| |
Fig. 8. XlFli-depleted embryos displayed phenotypes similar to Xapelin- and Xmsr-depleted embryos. (A) Western blotting assessing the target sequence specificity of XlFliMO. XlFliMO (20 ng) inhibited translation of injected mRNA with its target sequence (lane 4), but not of mRNA with 5 silent mutations around the first methionine (lane 2). (B) ControlMO (20 ng)-injected embryo at stage 45. (C) XlFliMO (20 ng)-injected embryo at stage 45. (D) Embryos coinjected pCS2-XlFli 5m (20 pg) with XlFliMO (20 ng). (E) Graphs showing the frequencies of edematous embryos in MO- and/or DNA-injected embryos. Three independent experiments were performed and showed similar results. The graph shows the representative result of one experiment. (G) Expression of SCL, Nkx2.5, Tie2, α-globin, and cTnI in the controlMO-injected embryos. (L) Expressions of SCL, Nkx2.5, Tie2, α-globin, and cTnI in the XlFliMO-injected embryos. |
